Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability

, indicate that VLP displayed a moderate degree of metabolic stability. These outcomes correspond to a bi-daily administration of VLP. Enhancing the metabolic stability can enable more convenient dosage regimens, improving the overall therapeutic experience for patients. In silico research indicates that minor structural alterations to the methoxy group or the pyrrolidine moiety (96% metabolically labile) in the drug design may improve the safety profile and the metabolic stability of novel derivatives relative to VLP.